New Zealand markets closed

Laboratory Corporation of America Holdings (LH)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
254.99+4.85 (+1.94%)
At close: 04:00PM EST
254.99 0.00 (0.00%)
After hours: 05:12PM EST
Full screen
Trade prices are not sourced from all markets
Previous close250.14
Open249.78
Bid0.00 x 800
Ask0.00 x 1000
Day's range247.35 - 256.01
52-week range200.32 - 290.20
Volume847,414
Avg. volume671,308
Market cap22.592B
Beta (5Y monthly)1.05
PE ratio (TTM)13.69
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.88 (1.15%)
Ex-dividend date22 Feb 2023
1y target estN/A
  • Business Wire

    Labcorp to Announce Fourth Quarter and Full Year 2022 Financial Results on February 16, 2023

    BURLINGTON, N.C., January 18, 2023--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2022 before the market opens on Thursday, Feb. 16, 2023. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.

  • Business Wire

    Labcorp Declares Quarterly Dividend

    BURLINGTON, N.C., January 12, 2023--Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 13, 2023, to stockholders of record as of the close of business on Feb. 23, 2023.

  • Business Wire

    Thomas Pike to Join Labcorp as President and Chief Executive Officer of Its Drug Development Clinical Development Business Unit

    BURLINGTON, N.C., January 05, 2023--Labcorp (NYSE: LH), a leading global life sciences company, today announced that Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit on Jan. 9, 2023. Until the planned spin-off of the Clinical Development business, which is expected to occur in mid-2023, Mr. Pike will report to Labcorp’s chairman and CEO Adam Schechter. At the time of the spin-off, Mr. Pike will serve as the ch